Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,577
  • Shares Outstanding, K 42,748
  • Annual Sales, $ 1,380 K
  • Annual Income, $ -179,050 K
  • EBIT $ -77 M
  • EBITDA $ -76 M
  • 60-Month Beta 0.11
  • Price/Sales 9.77
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.16
  • Most Recent Earnings $-0.32 on 11/14/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 321.09% ( +89.45%)
  • Historical Volatility 111.32%
  • IV Percentile 92%
  • IV Rank 36.88%
  • IV High 841.79% on 11/19/24
  • IV Low 16.84% on 06/04/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 121
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 6,391
  • Open Int (30-Day) 5,897

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.31
  • Low Estimate -0.49
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +47.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3001 +13.63%
on 12/20/24
0.5801 -41.22%
on 11/21/24
-0.2470 (-42.01%)
since 11/20/24
3-Month
0.3001 +13.63%
on 12/20/24
0.8300 -58.92%
on 10/30/24
-0.2356 (-40.86%)
since 09/20/24
52-Week
0.3001 +13.63%
on 12/20/24
4.1700 -91.82%
on 02/06/24
-2.6290 (-88.52%)
since 12/20/23

Most Recent Stories

More News
The Next Wave of Health AI: Analysts Highlight Breakthroughs in Clinical Trials and Patient Care

USA News Group  Commentary Issued on behalf of Avant Technologies Inc.   Vancouver, BC – December 17, 2024  – USA News Group News Commentary – Artificial intelligence (AI) is on the brink of becoming...

HWAIF : 1.4000 (-1.41%)
AIDX.TO : 2.00 (-2.91%)
AVAI : 0.5600 (+1.80%)
BTAI : 0.3410 (+8.12%)
RDNT : 72.70 (+1.85%)
ICAD : 1.8300 (+3.39%)
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

BTAI : 0.3410 (+8.12%)
BioXcel Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants

BioXcel Therapeutics announces an underwritten public offering of common stock and warrants to fund clinical trials and operations.Quiver AI SummaryBioXcel Therapeutics, Inc. has announced the launch of...

BTAI : 0.3410 (+8.12%)
BioXcel Therapeutics Announces Proposed Public Offering

BTAI : 0.3410 (+8.12%)
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

BTAI : 0.3410 (+8.12%)
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

BTAI : 0.3410 (+8.12%)
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

BTAI : 0.3410 (+8.12%)
BioXcel Therapeutics to Present at ThinkEquity Conference

BTAI : 0.3410 (+8.12%)
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BTAI : 0.3410 (+8.12%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
EXEL : 33.29 (-1.16%)
PFE : 26.36 (+2.29%)
BTAI : 0.3410 (+8.12%)
BMY : 57.33 (+1.83%)

Business Summary

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film...

See More

Key Turning Points

3rd Resistance Point 0.4007
2nd Resistance Point 0.3724
1st Resistance Point 0.3567
Last Price 0.3410
1st Support Level 0.3127
2nd Support Level 0.2844
3rd Support Level 0.2687

See More

52-Week High 4.1700
Fibonacci 61.8% 2.6917
Fibonacci 50% 2.2350
Fibonacci 38.2% 1.7784
Last Price 0.3410
52-Week Low 0.3001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar